Investigating Participation Patterns of Patients in Atopic Dermatitis Clinical Trials
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Atopic Dermatitis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Understanding Patient Engagement Trends in Atopic Dermatitis Clinical Research
Overview
Clinical trials, specifically focused on atopic dermatitis, are crucial in assessing the safety and efficacy of new treatments. These trials serve as fundamental instruments in determining whether emerging medications outperform standard therapies, providing compelling evidence to support wider implementation. The main goal is to thoroughly scrutinize trial completion rates and voluntary withdrawals among this particular group of patients.
Primary outcome measures
- Number of atopic dermatitis patients who decide to enroll in a clinical research [Time frame: 3 months]
- Rate of atopic dermatitis patients who remain in clinical trial to trial completion [Time frame: 12 months]
Eligibility criteria
Inclusion criteria
- Ability to understand and the willingness to sign a written informed consent document
- Participant must be 18 years of age or older
- Confirmed diagnosis of atopic dermatitis
Exclusion criteria
- Enrolled in another research study
- Is pregnant, breastfeeding or expecting to conceive within the projected duration of the study
- Inability to provide written informed consent
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-crossover
Study locations
United States · 1 center
- Power Life Sciences — San Francisco
Publications
- Shalom G, Kridin K, Raviv KO, Freud T, Comaneshter D, Friedland R, Cohen AD, Ben-Amitai D. Atopic Dermatitis and Celiac Disease: A Cross-Sectional Study of 116,816 Patients. Am J Clin Dermatol. 2020 Feb;21(1):133-138. doi: 10.1007/s40257-019-00474-2. PMID 31679111
- Schut C, Dalgard FJ, Bewley A, Evers AWM, Gieler U, Lien L, Sampogna F, Stander S, Tomas-Aragones L, Vulink N, Finlay AY, Legat FJ, Titeca G, Jemec GB, Misery L, Szabo C, Grivcheva-Panovska V, Spillekom-van Koulil S, Balieva F, Szepietowski JC, Reich A, Roque Ferreira B, Lvov A, Romanov D, Marron SE, Gracia-Cazana T, Svensson A, Altunay IK, Thompson AR, Zeidler C, Kupfer J; ESDAP Study collaborato PMID 35041211
- Patruno C, Fabbrocini G, Longo G, Argenziano G, Ferrucci SM, Stingeni L, Peris K, Ortoncelli M, Offidani A, Amoruso GF, Talamonti M, Girolomoni G, Grieco T, Iannone M, Nettis E, Foti C, Rongioletti F, Corazza M, Veneri MD, Napolitano M; Dupilumab for Atopic Dermatitis of the Elderly (DADE) Study Group. Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermat PMID 33725337
Identifiers
NCT: NCT06174493 · 66783591